SHR 7390Alternative Names: SHR-7390
Latest Information Update: 22 Nov 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Nov 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (In adults; In the elderly; Late-stage disease; Metastatic disease) in China (NCT02968485)
- 07 Oct 2016 Preclinical trials in Solid tumours in China (PO) before October 2016 (NCT02968485)